PROIN® Chewable Tablets

PROIN® Chewable Tablets

(phenylpropanolamine hydrochloride)
  • Category
    Urinary Health
  • Species
  • Supplied

    Flavored Chewable Tablets
    25 mg/60 ct. 25 mg/180 ct.
    50 mg/60 ct. 50 mg/180 ct.
    75 mg/60 ct. 75 mg/180 ct.

The Only FDA Approved Phenylpropanolamine Hydrochloride Medication For The Treatment Of Urinary Incontinence Due To Urethral Sphincter Hypotonus.


For oral use in dogs only. Not for human use. Keep out of reach of children. If accidentally ingested by humans, contact a physician immediately.

The most commonly reported side effects were vomiting, loss of appetite, diarrhea, excessive salivation, agitation, tiredness, vocalization, confusion, increased water consumption, weight loss, weakness, fever, panting, and reversible changes in skin color (flushing or bright pink). Abnormal gait, seizures or tremors, as well as liver enzyme elevations, kidney failure, blood in urine and urine retention have been reported. In some cases death, including euthanasia has been reported. Sudden death was sometimes preceded by vocalization or collapse.

Instances of dogs chewing through closed vials of PROIN® and eating the vial contents have been reported, in some cases resulting in overdose. Keep the product in a secured storage area out of the reach of pets in order to prevent accidental ingestion or overdose, as dogs may willingly consume more than the recommended dosage of PROIN Chewable tablets. Contact your veterinarian immediately if the dog ingests more tablets than prescribed or if other pets ingest PROIN Chewable tablets.

PROIN may cause elevated blood pressure and should be used with caution in dogs with pre-existing heart disease, high blood pressure, liver disease, kidney insufficiency, diabetes, glaucoma, and other conditions associated with high blood pressure.

The safe use of PROIN in dogs used for breeding purposes, during pregnancy or in lactating bitches, has not been evaluated. Contact your veterinarian if you notice restlessness or irritability, loss of appetite, the incontinence persists or worsens or any other unusual signs. See prescribing information for complete details regarding adverse events, warning and precautions.

(phenylpropanolamine hydrochloride)
For the control of canine urinary incontinence due to urethral sphincter hypotonus.

Urethral sphincter hypotonus causes canine urinary incontinence as a result of weakened muscles of the urethral sphincter.

NADA# 141-324

PROIN® works by increasing urethral sphincter muscle tone to help prevent urinary accidents.

What are the common clinical signs of urinary incontinence in dogs?

  • Dripping or leaking urine
  • Excessive licking of the genital area
  • Red and irritated skin around the genital area
  • Needing to go more frequently than normal
  • Wetting the bed or sleeping area
  • Urinating inappropriately in the house

Fortunately, while frustrating at first, canine urinary incontinence may be controlled with PROIN®, a safe and effective FDA-approved chewable tablet that works by increasing urethral sphincter tone to help prevent urinary accidents.


  • Only FDA approved PPA for the treatment of urinary incontinence due to urethral sphincter hypotenuse with proven efficacy.
  • Offers three tablet strengths of half scored, liver-flavored tablets allowing health care providers to tailor the dosage for most dogs.
  • Formulated as a liver-flavored tablet to help make dosing easier.

As Seen On

CAUTION: Federal law restricts this drug to be used by or on the order of a licensed veterinarian.
  • Detailed Overview
  • Resources
  • FIOS

Detailed Overview


For the control of urinary incontinence due to urethral sphincter hypotonus in dogs.

Dosage and Administration

Dosing directions provided are for guidance only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

For more information about dosage and administration, click here.

Active Ingredient

phenylpropanolamine hydrochloride


Study Information


PROIN® administered to dogs twice daily for 28 days was effective in controlling urinary incontinence based on an 82% decrease in urinary accidents in female dogs and 58% urinary accident decrease in male dogs over the 4 week treatment period (compared to decreased accident rate of 64% in females and 48% in males in the placebo group). With continued dosing for 180 days, PROIN was effective for the control of urinary incontinence based on 98.1 % owner satisfaction. The dogs averaged just over one accident per dog per week. 1, 2